Table II.
Analyte | T max (h) | C max (ng/ml) | MRT (h) | AUClast (ng*h/ml), PO | Bioavailability, F | Fold increase in F | |||||
---|---|---|---|---|---|---|---|---|---|---|---|
GE | Mix | GE | Mix | GE | Mix | GE | Mix | GE | Mix | ||
6G | 0.17 | 0.08 | 305.9±92.45 | 300.69±2.95 | 3.95 | 3.34 | 219.04 | 137.97 | 110 | 69 | 1.6 |
8G | 0.17 | 0.08 | 71.74±32.61 | 144.71±0.49 | 2.81 | 1.45 | 48.65 | 44.49 | 84 | 77 | 1.1 |
10G | 0.17 | 0.08 | 327.26±40.12 | 756.62±7.62 | 4.57 | 1.34 | 957.34 | 281.56 | 385 | 113 | 3.4 |
6S | 0.17 | 0.08 | 5.68±0.18 | 10.57±4.72 | 4.63 | 2.10 | 7.37 | 2.97 | 330 | 133 | 2.5 |
F, bioavailability—calculated using dose normalized AUClast; MRT: mean residence time; PO, single oral dose.